Enanta Pharmaceuticals | ENTA - Des Atouts

Prix De L'Action
12.62
Variation Quotidienne
0.11 0.88%
Mensuellement
-14.44%
Annuel
103.55%
Q1 Prévisions
12.13




Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Amgen USD 90.59B 445M 2025-12
Anika Therapeutics USD 190.27M 833K 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Biogen USD 29.44B 232M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Immunic USD 40.7M 20.72M 2025-09
Incyte USD 6.96B 627.62M 2025-12
Insmed USD 2.26B 96.18M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
J&J USD 199.21B 6.39B 2025-12
Karyopharm Therapeutics USD 96.23M 8.65M 2025-09
Ligand Pharmaceuticals USD 1.56B 83.86M 2025-12
Merck USD 129.55B 12.02B 2025-09
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Novavax USD 1.18B 3.38M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12